"We hope to move this vaccine candidate into clinical trials soon and to continue producing vaccines for other diseases as well." Just as a leather soccer ball is stitched from geometric patterns, the new vaccine's core is a computer-designed nanoparticle made of different parts shaped like pentagons and triangles.Each nanoparticle is more than ten million times smaller than a poppy seed.Tags: How To Start Your Own Wedding Planning BusinessSchizophrenia Essay ConclusionHospitality Dissertation TopicsTemple University Mfa Program Creative WritingOxbridge Essays Times4 Paragraph Essay OutlineEssay On German CultureAssignment Of PhysicsSamantha Bremner ThesisHigh School Freshman Research Paper
"We will continue to develop this technology so that we and others can make new vaccines better, cheaper, and faster.
We are excited to work with our many partners and collaborators to translate our work in the lab into actual vaccines that go out into the world and, hopefully, save lives." The RSV vaccine team was led by researchers at UW Medicine and the Institute for Research in Biomedicine in Bellinzona, Switzerland.
Their use in this study is part of a larger trend called structure-based vaccine design. Using computationally designed protein nanoparticles, however, allows for much more control over important vaccine properties, such as overall size, stability, and the number of antigens presented to the immune system.
Recently, scientists have repurposed natural nanoparticles to create experimental vaccines for HIV, hepatitis C, and other diseases, according to a Feb. "This is the first of many vaccine candidates we have made using this technology," said senior author Neil King, assistant professor of biochemistry at the UW School of Medicine.
RSV infects nearly all children by the age of three.
Infection typically causes mild symptoms, but can be more serious in newborns, immunocompromised individuals and the elderly.As yet no RSV vaccine is ready for use in disease prevention."It has historically been challenging to produce an RSV vaccine that is both safe and effective, but exciting new vaccine design strategies continue to emerge," said Brooke Fiala, a research scientist at the University of Washington School of Medicine's Institute for Protein Design and a lead author of the study.About 99 percent of the RSV deaths occur in developing countries.After considerable research, several vaccine candidates are in preclinical or clinical testing.A study of infant feeding practices was carried out on a sample of 100 mother and infant pairs.The results revealed that only 20% of mothers in the study currently exclusively breastfeed their babies.This finding suggests it may translate into a more effective vaccine with more durable protection.Nanoparticles are already known to give vaccines a boost.It also included scientists from Fred Hutch Cancer Research Center in Seattle, Karolinska Institute in Stockholm, Sweden; Vaccine Formulation Institute in Godalming, United Kingdom; European Virus Bioinformatics Center in Jena, Germany; the Vaccine Formulation Laboratory at the University of Lausanne, Switzerland; and the Institute of Microbiology at the Swiss Federal Institute of Technology (ETH Zu? Several of the Seattle researchers have launched a biotech company called Icosavax to manufacture the RSV vaccine candidate and evaluate it in clinical trials.Icosavax will also apply the nanoparticle platform to design and test vaccines for other infectious diseases.